Spectrum's EOquin trial shows antitumor effect in 30 out of 46 patients

By Elaine Rigoli

Tampa, Fla., April 6 - Spectrum Pharmaceuticals, Inc. said the results of a phase 2 marker lesion study of EOquin (apaziquone) formulated for administration directly into the urinary bladder in superficial bladder cancer showed the complete disappearance of the tumor in 30 patients.

A total of 46 patients with multiple lesions of superficial bladder cancer were entered into this multi-center study, according to a news release.

After surgical removal of all except one "marker" lesion, patients received six weekly instillations of EOquin into the bladder.

Superficial bladder cancer accounts for 75% to 85% of all cases of bladder cancer at first diagnosis. The initial treatment is usually surgical removal of the tumor, often followed by additional immunotherapy or chemotherapy drugs instilled directly in the bladder to prevent or delay recurrences.

The company said it is planning to start a small pilot study, which should be followed by a randomized phase 3 trial before the end of this year.

Spectrum Pharmaceuticals is a specialty pharmaceutical company based in Irvine, Calif., that develops prescription drug products for the treatment of cancer and other unmet medical needs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.